LAUSR

The top three urologic cancers in terms of mortality are PC (3.8%), bladder cancer (2.1%), and kidney cancer (2.1%) among all cancers in 2020. 1 The determination of therapeutic sensi-tivity based on genomic alteration has been used to improve therapeutic effects in cancer patients. 2 Cancer results from the accumulation of mutations; thus, genomic testing using NGS has been widely applied in the evaluation of clinical utility. 3,4 It is reported that genomic alterations can be raised during the development of therapeutic resistance. 5 Therefore, knowledge of the landscape of genomic alterations in treatment-na € ı ve cancers would be useful to understand whether the genomic alteration is induced by treatment. In this study, we report the genomic pro fi ling of treatment-na € ı ve Japanese urological cancers, including RCC, PC, and UC. This a study conducted by reviewing the genomic alteration data of 105 cancers (RCC, and druggable cancer genomic alterations in UC.